Literature DB >> 29902577

Early metastatic colorectal cancers show increased tissue expression of miR-17/92 cluster members in the invasive tumor front.

Rikke Karlin Jepsen1, Guy Wayne Novotny2, Louise Laurberg Klarskov3, Claus Heiner Bang-Berthelsen4, Ida Trondhjem Haakansson5, Anker Hansen6, Ib Jarle Christensen7, Lene Buhl Riis8, Estrid Høgdall9.   

Abstract

Accurate prediction of regional lymph node metastases (LNM) in endoscopically resected pT1 colorectal cancer (CRC) is crucial in treatment stratification for subsequent radical surgery. Several miRNAs have been linked to CRC invasion and metastasis, including the oncogenic miR-17/92 cluster, and expression levels might have predictive value in the risk assessment of early metastatic progression in CRC. We performed global miRNA microarray using tissue samples from the invasive front of pT1 CRC and investigated associations of the miR-17/92 cluster and presence of LNM. In total, 56 matched pT1 CRCs were thoroughly clinicopathologically characterized, and miRNA microarrays were performed on invasive front tissue samples. Global miRNA intensities were screened using paired t-tests between pT1pN+ and pT1pN0. Associations between miR-17/92 and histopathological features were analyzed using general linear models and tumor cell adjusted expression intensities. miR-17-3p and miR-92a were significantly higher expressed in the invasive front of tumors with LNM compared to those without, corresponding to 1.53-fold higher expression of miR-17-3p (95%CI: 1.04-2.24, P = .030) and 1.28-fold higher expression of miR-92a (95%CI: 1.01-1.68, P = .042). An inverse association between miR-19a and presence of high-grade tumor budding was observed (1.55-fold, 95%CI: 1.13-2.12, P = .008). We provide evidence for associations between early regional LNM and high expression levels of the miR-17/92 cluster members: miR-17-3p and miR-92a, in the invasive front of CRC. Our results support a role for the miR-17/92 cluster in early metastatic progression of CRC and calls for further investigation.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; Invasive tumor front; Metastases; MiR-17/92; MicroRNA; Microarray; pT1

Mesh:

Substances:

Year:  2018        PMID: 29902577     DOI: 10.1016/j.humpath.2018.05.027

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  5 in total

1.  Elevated ZBTB7A expression in the tumor invasive front correlates with more tumor budding formation in gastric adenocarcinoma.

Authors:  Yujing Sun; Junyi He; Duan-Bo Shi; Hui Zhang; Xu Chen; Ai-Yan Xing; Peng Gao
Journal:  J Cancer Res Clin Oncol       Date:  2020-09-23       Impact factor: 4.553

2.  Construction and prognostic analysis of miRNA-mRNA regulatory network in liver metastasis from colorectal cancer.

Authors:  Ruyun Cai; Qian Lu; Da Wang
Journal:  World J Surg Oncol       Date:  2021-01-04       Impact factor: 2.754

Review 3.  TRIM Proteins in Colorectal Cancer: TRIM8 as a Promising Therapeutic Target in Chemo Resistance.

Authors:  Flaviana Marzano; Mariano Francesco Caratozzolo; Graziano Pesole; Elisabetta Sbisà; Apollonia Tullo
Journal:  Biomedicines       Date:  2021-02-27

4.  Transcriptome analysis reveals upregulation of immune response pathways at the invasive tumour front of metastatic seminoma germ cell tumours.

Authors:  Tim Nestler; Priya Dalvi; Friederike Haidl; Maike Wittersheim; Melanie von Brandenstein; Pia Paffenholz; Svenja Wagener-Ryczek; David Pfister; Ulrike Koitzsch; Martin Hellmich; Reinhard Buettner; Margarete Odenthal; Axel Heidenreich
Journal:  Br J Cancer       Date:  2022-01-12       Impact factor: 9.075

5.  MicroRNA-17-92a-1 Host Gene (MIR17HG) Expression Signature and rs4284505 Variant Association with Alopecia Areata: A Case-Control Study.

Authors:  Salwa Faisal; Eman A Toraih; Lina M Atef; Ranya Hassan; Marwa M Fouad; Essam Al Ageeli; Manal S Fawzy; Hussein Abdelaziz Abdalla
Journal:  Genes (Basel)       Date:  2022-03-12       Impact factor: 4.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.